Granlibakken Tahoe Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2016
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Drug Discovery for Parasitic Diseases (A5)
Organizer(s) Leann M. Tilley, Philip J. Rosenthal and Kelly Chibale
January 24—28, 2016
Granlibakken Tahoe • Tahoe City, CA USA
Discounted Abstract Deadline: Sep 28, 2015
Abstract Deadline: Oct 28, 2015
Scholarship Deadline: Sep 28, 2015
Discounted Registration Deadline: Nov 23, 2015
Supported by the Directors' Fund
Summary of Meeting:
Parasitic organisms, including protozoa and helminths, are among the most significant human pathogens, causing billions of infections and millions of deaths each year. For many parasitic diseases, available therapies are unsatisfactory and increasingly threatened by drug resistance. New therapies, ideally directed against novel targets, are urgently needed. Recent advances in anti-parasitic drug discovery have come from three different approaches – target-based methods that build on improved understanding of parasite biology; phenotypic high-throughput screens that are benefitting from improved technology; and repositioning and repurposing drugs developed for other indications. These different approaches all benefit from the integration of medicinal chemistry with parasitology and pharmacotherapy programs. This conference will showcase cutting-edge anti-parasitic drug discovery programs that illustrate the path from parasite biology to lead identification and from optimization to candidate selection. It will emphasize the need for coordinated integration of programs in medicinal chemistry, parasite biology, pharmacokinetics and safety assessment. It will feature emerging technologies such as chemical biology, chemoproteomics, chemical informatics, genomics, transcriptomics and metabolomics that are facilitating drug discovery. It will also discuss the current status of anti-parasitic drug resistance and advances in our understanding of mechanisms of resistance. The conference should be of interest to medicinal chemists, parasitologists, experts in drug discovery and development, pharmacologists and clinicians targeting the protozoa and helminths that cause serious human disease, including malaria, African and American trypanosomiasis, leishmaniasis, schistosomiasis and multiple other parasitic infections.
View Scholarships/Awards
Parasitic organisms, including protozoa and helminths, are among the most significant human pathogens, causing billions of infections and millions of deaths each year. For many parasitic diseases, available therapies are unsatisfactory and increasingly threatened by drug resistance. New therapies, ideally directed against novel targets, are urgently needed. Recent advances in anti-parasitic drug discovery have come from three different approaches – target-based methods that build on improved understanding of parasite biology; phenotypic high-throughput screens that are benefitting from improved technology; and repositioning and repurposing drugs developed for other indications. These different approaches all benefit from the integration of medicinal chemistry with parasitology and pharmacotherapy programs. This conference will showcase cutting-edge anti-parasitic drug discovery programs that illustrate the path from parasite biology to lead identification and from optimization to candidate selection. It will emphasize the need for coordinated integration of programs in medicinal chemistry, parasite biology, pharmacokinetics and safety assessment. It will feature emerging technologies such as chemical biology, chemoproteomics, chemical informatics, genomics, transcriptomics and metabolomics that are facilitating drug discovery. It will also discuss the current status of anti-parasitic drug resistance and advances in our understanding of mechanisms of resistance. The conference should be of interest to medicinal chemists, parasitologists, experts in drug discovery and development, pharmacologists and clinicians targeting the protozoa and helminths that cause serious human disease, including malaria, African and American trypanosomiasis, leishmaniasis, schistosomiasis and multiple other parasitic infections.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, January 24 with registration from 16:00 to 20:00 and a welcome mixer and light meal from 18:00 to 20:00. Conference events conclude on Thursday, January 28 with a closing plenary session from 17:00 to 19:00, followed by dinner and entertainment. We recommend return travel on Friday, January 29 in order to fully experience the meeting.
SUNDAY, JANUARY 24
MONDAY, JANUARY 25
TUESDAY, JANUARY 26
WEDNESDAY, JANUARY 27
THURSDAY, JANUARY 28
FRIDAY, JANUARY 29
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, January 24 with registration from 16:00 to 20:00 and a welcome mixer and light meal from 18:00 to 20:00. Conference events conclude on Thursday, January 28 with a closing plenary session from 17:00 to 19:00, followed by dinner and entertainment. We recommend return travel on Friday, January 29 in order to fully experience the meeting.
SUNDAY, JANUARY 24
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Welcome and Keynote Address
*
Leann M. Tilley,
University of Melbourne, Australia
Elizabeth A. Winzeler,
University of California, San Diego, USA
Antimalarial Drug Discovery: From Phenotypic Screen to Novel Hits to Target Identification to Preclinical Studies
Antimalarial Drug Discovery: From Phenotypic Screen to Novel Hits to Target Identification to Preclinical Studies
09:00—11:15
Clinical Development and Evaluation
*
R. Kip Guy,
St. Jude Children's Research Hospital, USA
*
Lawrence R. Dick,
, USA
Annette Kuesel,
World Health Organization, Switzerland
Clinical Development of Drugs for Control and Elimination of Helminthic Diseases
Clinical Development of Drugs for Control and Elimination of Helminthic Diseases
Philip J. Rosenthal,
University of California, San Francisco, USA
Changing Malaria Treatment Efficacy with Changes in Treatment Practices and Drug Sensitivities in Uganda
Changing Malaria Treatment Efficacy with Changes in Treatment Practices and Drug Sensitivities in Uganda
Shyam Sundar,
Banaras Hindu University, India
Clinical Trials for the Treatment of Visceral Leishmaniasis
Clinical Trials for the Treatment of Visceral Leishmaniasis
Ian H. Gilbert,
University of Dundee, UK
Short Talk: A Fully Integrated Partnership Performing Drug Discovery towards Visceral Leishmaniasis
Short Talk: A Fully Integrated Partnership Performing Drug Discovery towards Visceral Leishmaniasis
17:00—18:40
Target-Based Screening
*
Rob Leurs,
Vrije Universiteit Amsterdam, Netherlands
*
Tanya Paquet,
University of Cape Town, South Africa
James H. McKerrow,
University of California, San Diego, USA
Target-Based Drug Discovery: Targeting Cysteine Proteases in Multiple Organisms
Target-Based Drug Discovery: Targeting Cysteine Proteases in Multiple Organisms
Matthew S. Bogyo,
Stanford University School of Medicine, USA
Structure and Function-Based Design of Plasmodium-Selective Proteasome Inhibitors
Structure and Function-Based Design of Plasmodium-Selective Proteasome Inhibitors
Meg Phillips,
University of Texas Southwestern Medical Center, USA
A Clinical Candidate Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase
A Clinical Candidate Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase
18:40—19:00
Black Diamonds (2 minute poster teaser talks)
*
Christopher Dean Goodman,
University of Melbourne, Australia
*
Philip J. Rosenthal,
University of California, San Francisco, USA
Sneha Anand,
Jawahar Lal Nehru University, India
Characterization of Essential Non-Translational Function of Leishmania Tyrosyl tRNA Synthetase and its Prospect as a Drug Target
Characterization of Essential Non-Translational Function of Leishmania Tyrosyl tRNA Synthetase and its Prospect as a Drug Target
Ximena Barros-Alvarez,
University of Washington, USA
Structural Biology in the Development of Inhibitors Targeting Methionyl-tRNA Synthetase for the Discovery of New Therapeutics to Treat Sleeping Sickness
Structural Biology in the Development of Inhibitors Targeting Methionyl-tRNA Synthetase for the Discovery of New Therapeutics to Treat Sleeping Sickness
Jessica L. Bridgford,
University of Melbourne, Australia
Targeting Artemisinin Resistance in the Malaria Parasite Plasmodium falciparum
Targeting Artemisinin Resistance in the Malaria Parasite Plasmodium falciparum
Lynn Dong Blake,
Central Michigan University College of Medicine, USA
Characterization of Menoctone Efficacy Against Plasmodium Berghei and P. falciparum
Characterization of Menoctone Efficacy Against Plasmodium Berghei and P. falciparum
Brian R. Blank,
University of California, San Francisco, USA
In Vitro and in vivo Investigation of Regioisomeric Forms of Arterolane-Like Endoperoxides
In Vitro and in vivo Investigation of Regioisomeric Forms of Arterolane-Like Endoperoxides
Stephanie Braillard,
Drugs for Neglected Diseases Initiative, Switzerland
DNDI-0690: A New Promising Drug Candidate for the Treatment of Visceral Leishmaniasis
DNDI-0690: A New Promising Drug Candidate for the Treatment of Visceral Leishmaniasis
Angela Kelly Carrillo Alocen,
St Jude Children's Research Hospital, USA
Towards the Determination of the Mechanism of Action of the Chloronitrobenzamides against Trypanosoma brucei brucei
Towards the Determination of the Mechanism of Action of the Chloronitrobenzamides against Trypanosoma brucei brucei
Victoria Catherine Corey,
University of California, San Diego, USA
Comprehensive Analysis of Resistance Development in the Malaria Parasite
Comprehensive Analysis of Resistance Development in the Malaria Parasite
Manu De Rycker,
University of Dundee, UK
Tailored Hit-Discovery Cascades for Leishmania donovani and Trypanosoma cruzi that Combine High-Throughput Screening with Multiple Secondary Assays to Build Confidence in Hits
Tailored Hit-Discovery Cascades for Leishmania donovani and Trypanosoma cruzi that Combine High-Throughput Screening with Multiple Secondary Assays to Build Confidence in Hits
Gregory Goldgof,
University of California, San Diego, USA
Synthetic Drug Sensitive Yeast as a Tool for Drug Target Discovery
Synthetic Drug Sensitive Yeast as a Tool for Drug Target Discovery
Rob Leurs,
Vrije Universiteit Amsterdam, Netherlands
Phenotypic Screening Identifies Human PDE4 Inhibitors with Submicromolar Activity Against Trypanosoma Cruzi, the Causative Agent of Chagas Disease
Phenotypic Screening Identifies Human PDE4 Inhibitors with Submicromolar Activity Against Trypanosoma Cruzi, the Causative Agent of Chagas Disease
Ebere Sonoiki,
University of California, San Francisco, USA
Two Novel p. Falciparum Targets Identified by Different Benzoxaboroles
Two Novel p. Falciparum Targets Identified by Different Benzoxaboroles
08:00—11:15
Phenotypic Screening, Repurposing and Repositioning
*
Jane Kelly,
Portland State University, USA
*
Leslie Street,
University of Cape Town, South Africa
Jeremy N. Burrows,
Medicines for Malaria Venture, Switzerland
Drug Discovery to Control and Eradicate Malaria
Drug Discovery to Control and Eradicate Malaria
Michael H. Gelb,
University of Washington, USA
A Phenotypic Approach to Drug Discovery for Stage II Human African trypanosomiasis
A Phenotypic Approach to Drug Discovery for Stage II Human African trypanosomiasis
Jennifer Keiser,
Swiss Tropical and Public Health Institute, Switzerland
Repurposing for Antischistosomal Drug Discovery: From Bench to Field
Repurposing for Antischistosomal Drug Discovery: From Bench to Field
John Haselden,
GlaxoSmithKline, Spain
Antiparasitic Hits from Phenotypic High Throughput Screening
Antiparasitic Hits from Phenotypic High Throughput Screening
Amy K. Wernimont,
National Institutes of Health, USA
Short Talk: Collaborative Drug Discovery and Structural Genomics – Impact for Neglected Disease Research
Short Talk: Collaborative Drug Discovery and Structural Genomics – Impact for Neglected Disease Research
Charles E. Mowbray,
Drugs for Neglected Diseases Initiative, Switzerland
Short Talk: The NTD Drug Discovery Booster: A Novel Approach for Hit to Lead Chemistry
Short Talk: The NTD Drug Discovery Booster: A Novel Approach for Hit to Lead Chemistry
14:30—16:30
Workshop and Panel: Drug Target to Clinic: The Pipeline
*
Kelly Chibale,
University of Cape Town, South Africa
Meg Phillips,
University of Texas Southwestern Medical Center, USA
Target Validation and the Comparison of Target-Based HTS versus Whole Organism Screening
Target Validation and the Comparison of Target-Based HTS versus Whole Organism Screening
Timothy G. Geary,
McGill University, Canada
Moving from Concept to Reality for Repurposing an Approved Drug for a New Neglected Disease Indication
Moving from Concept to Reality for Repurposing an Approved Drug for a New Neglected Disease Indication
Kevin Read,
University of Dundee, UK
NTD Drug Discovery: An Academic Perspective
NTD Drug Discovery: An Academic Perspective
Robert T. Jacobs,
Anacor Pharmaceuticals, Inc., USA
Parasitic/Neglected Disease Drug Discovery: A Biotech Perspective
Parasitic/Neglected Disease Drug Discovery: A Biotech Perspective
John Haselden,
GlaxoSmithKline, Spain
A Pharma Perspective on Opportunities to Transition Drug Discovery Assets into Preclinical and Early Clinical Drug Development
A Pharma Perspective on Opportunities to Transition Drug Discovery Assets into Preclinical and Early Clinical Drug Development
Jeremy N. Burrows,
Medicines for Malaria Venture, Switzerland
Practical Issues in Translating Antimalarial Drugs
Practical Issues in Translating Antimalarial Drugs
Susan A. Charman,
Monash University, Australia
Human Pharmacokinetic and Dose Predictions
Human Pharmacokinetic and Dose Predictions
Annette Kuesel,
World Health Organization, Switzerland
What Support do Regulatory Agencies Offer
What Support do Regulatory Agencies Offer
17:00—18:40
Hit to Lead
*
Debopam Chakrabarti,
University of Central Florida, USA
*
Audrey R. Odom,
Washington University School of Medicine, USA
Jonathan L. Vennerstrom,
University of Nebraska Medical Center, USA
Discovery of Antimalarial Ozonides OZ277 and OZ439
Discovery of Antimalarial Ozonides OZ277 and OZ439
Kelly Chibale,
University of Cape Town, South Africa
Antimalarials from SoftFocus Libraries: Optimization and Target Identification
Antimalarials from SoftFocus Libraries: Optimization and Target Identification
Robert T. Jacobs,
Anacor Pharmaceuticals, Inc., USA
Drug Discovery and Development Based on Antiparasitic Benzoxaboroles
Drug Discovery and Development Based on Antiparasitic Benzoxaboroles
18:40—19:05
Short Schusses (2 minute poster teaser talks)
*
Darren J. Creek,
Monash University, Australia
*
Leann M. Tilley,
University of Melbourne, Australia
Rajiv S. Jumani,
University of Vermont, USA
Methods to Prioritize Anti-Cryptosporidium Hits
Methods to Prioritize Anti-Cryptosporidium Hits
Leah S. Imlay,
Washington University in St. Louis, USA
Structure-Activity Relationship Studies of the Malaria Box Compound 1R,3S-MMV008138, Inhibitor of the Non-Mevalonate Pathway Enzyme IspD
Structure-Activity Relationship Studies of the Malaria Box Compound 1R,3S-MMV008138, Inhibitor of the Non-Mevalonate Pathway Enzyme IspD
Benoit Laleu,
Medicines for Malaria Venture, Switzerland
The Pathogen Box Project: A Catalyst for Neglected Disease Drug Discover
The Pathogen Box Project: A Catalyst for Neglected Disease Drug Discover
Cynthia Lichorowic,
Northeastern University, USA
Orally Bioavailable and In Vivo Efficacious Antimalarial 4(1H)-Quinolones
Orally Bioavailable and In Vivo Efficacious Antimalarial 4(1H)-Quinolones
Stephan Meister,
University of California, San Diego, USA
A High-Throughput Luciferase-Based Assay for the Discovery of Malaria Liver Stage Therapeutics
A High-Throughput Luciferase-Based Assay for the Discovery of Malaria Liver Stage Therapeutics
Jane C. Munday,
University of Glasgow, UK
Functional Analysis of Parasitic PDEs Towards Validation as Potential Drug Targets
Functional Analysis of Parasitic PDEs Towards Validation as Potential Drug Targets
Caroline Ng,
University of Nebraska Medical Center, USA
PfMDR1 Mutations Protect Against a Novel Antimalarial but Confer Sensitivity to Partner Drugs in Artemisinin-Based Combination Therapy
PfMDR1 Mutations Protect Against a Novel Antimalarial but Confer Sensitivity to Partner Drugs in Artemisinin-Based Combination Therapy
Ferdinand Wafula Ndubi,
University of Cape Town, South Africa
Synthesis and Structure-Activity Relationship Studies of Antimalarial Pyrido [1, 2alpha] Benzimidazoles
Synthesis and Structure-Activity Relationship Studies of Antimalarial Pyrido [1, 2alpha] Benzimidazoles
John Okombo,
University of Cape Town, South Africa
Mechanistic Profiling of Dual-Functioning Reversed Chloroquine Compounds Containing a Dibenzylmethylamine Side Chain
Mechanistic Profiling of Dual-Functioning Reversed Chloroquine Compounds Containing a Dibenzylmethylamine Side Chain
Khan T. Osman,
University of Toronto, Canada
Discovery of Novel Dual-Kinase Inhibitors Against Parasite-Specific Protein Kinases
Discovery of Novel Dual-Kinase Inhibitors Against Parasite-Specific Protein Kinases
Sarah Preston,
University of Melbourne, Australia
Working Toward New Drugs Against Parasitic Worms in Public-Private Partnership
Working Toward New Drugs Against Parasitic Worms in Public-Private Partnership
Babu Somepalli Mastan,
University of Hyderabad, India
Probing the function of Aspartyl proteases, Plasmepsin VII & VIII in Plasmodium berghei
Probing the function of Aspartyl proteases, Plasmepsin VII & VIII in Plasmodium berghei
08:00—11:15
Drug Resistance
*
Elisabeth D. Martinez,
University of Texas Southwestern Medical Center, USA
*
Kellan C. Gregory,
Collaborative Drug Discovery Inc, USA
David A. Fidock,
Columbia University Medical Center, USA
Leveraging Genome Editing to Define the Genetic Basis of Antimalarial Drug Resistance
Leveraging Genome Editing to Define the Genetic Basis of Antimalarial Drug Resistance
Leann M. Tilley,
University of Melbourne, Australia
Molecular Basis of Artemisinin Action and Resistance
Molecular Basis of Artemisinin Action and Resistance
Marc Ouellette,
CIHR Institute of Infection and Immunity, Canada
Functional Genomics of Drug Resistance in Leishmania
Functional Genomics of Drug Resistance in Leishmania
Vern B. Carruthers,
University of Michigan Medical School, USA
Targeting a T. gondii Cathepsin Protease Essential for Chronic Toxoplasmosis
Targeting a T. gondii Cathepsin Protease Essential for Chronic Toxoplasmosis
Kirsten Hanson,
University of Texas at San Antonio, USA
Short Talk: Targeting Liver Stages of Malaria Parasites
Short Talk: Targeting Liver Stages of Malaria Parasites
17:00—18:40
Tackling Challenging Targets
*
Case W. McNamara,
Calibr at Scripps Research, USA
*
Rosa A. Maldonado,
University of Texas at El Paso, USA
Timothy G. Geary,
McGill University, Canada
Mechanism-Based Screening Against Nematode G Protein-Coupled Receptors: A Case History
Mechanism-Based Screening Against Nematode G Protein-Coupled Receptors: A Case History
Christophe Bodenreider,
Novartis Institute for Tropical Diseases, Singapore
Development of PI(4) Kinase Inhibitors Active across the Life-Cycle of Plasmodium
Development of PI(4) Kinase Inhibitors Active across the Life-Cycle of Plasmodium
Geoffrey Ian McFadden,
University of Melbourne, Australia
Parasite Resistance to the Antimalarial Atovaquone is not Transmissible by Mosquitoes
Parasite Resistance to the Antimalarial Atovaquone is not Transmissible by Mosquitoes
18:40—19:00
Screaming Snowboarders (2 minute poster teaser talks)
*
Paul Horrocks,
Keele University, UK
*
Kelly Chibale,
University of Cape Town, South Africa
Bracken Franklin Roberts,
University of Central Florida, USA
Identification of Novel Chemical Scaffolds that Inhibit All Stages of Plasmodium Asexual Life Cycle
Identification of Novel Chemical Scaffolds that Inhibit All Stages of Plasmodium Asexual Life Cycle
Vijeta Sharma,
Shiv Nadar University, India
Anti-Plasmodial Activity of Redox System Enzyme Inhibitor
Anti-Plasmodial Activity of Redox System Enzyme Inhibitor
Jair L. Siqueira-Neto,
University of California, San Diego, USA
Different Strategies to Find New Active Compounds to Treat Chagas Disease
Different Strategies to Find New Active Compounds to Treat Chagas Disease
Allison Michele Stickles,
Oregon Health & Science University, USA
Atovaquone and ELQ-300 Combination Therapy: A Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria
Atovaquone and ELQ-300 Combination Therapy: A Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria
Taher Uddin,
University of Melbourne, Australia
Validation of Putative Apicoplast Targeting Drugs Using a chemical Supplementation Assay in Cultured Malaria Parasites
Validation of Putative Apicoplast Targeting Drugs Using a chemical Supplementation Assay in Cultured Malaria Parasites
Manu Vanaerschot,
Columbia University, USA
Identifying Dihydropyridones as New Antimalarial Drug Candidates with Asexual Blood Stage and Gametocyte Activity
Identifying Dihydropyridones as New Antimalarial Drug Candidates with Asexual Blood Stage and Gametocyte Activity
Richard John Wall,
University of Dundee, UK
Defining Drug Mechanism of Action: Leveraging Phenotypic Hits Against Kinetoplastids
Defining Drug Mechanism of Action: Leveraging Phenotypic Hits Against Kinetoplastids
Leah Walker,
Johns Hopkins School of Public Health, USA
Short Talk: Duration of Artemisinin Combination Therapy Influences Parasitological Outcome in a Mouse Model of Malaria
Short Talk: Duration of Artemisinin Combination Therapy Influences Parasitological Outcome in a Mouse Model of Malaria
Clarisse Ricci,
University of California, San Diego, USA
Molecular Dynamics Investigation of Plasmodium vivax GGPPS and Implications for Computer-Aided Drug Discovery
Molecular Dynamics Investigation of Plasmodium vivax GGPPS and Implications for Computer-Aided Drug Discovery
08:00—11:15
Genomics, Proteomics and Metabolomics and New Technologies
*
Kirsten Hanson,
University of Texas at San Antonio, USA
*
Stuart A. Ralph,
University of Melbourne, Australia
Sarah K. Volkman,
Harvard T.H. Chan School of Public Health, USA
Genome Wide Association Studies to Gain Insights into Drug Resistance
Genome Wide Association Studies to Gain Insights into Drug Resistance
Sonja Ghidelli-Disse,
Cellzome, a GSK company, Germany
Use of Chemoproteomics to Identify Parasite Targets
Use of Chemoproteomics to Identify Parasite Targets
Malcolm J. McConville,
University of Melbourne, Australia
Measuring Parasite Metabolism in vivo
Measuring Parasite Metabolism in vivo
Collette Britton,
University of Glasgow, UK
Small RNAs: Association with Anthelmintic Resistance and as Potential New Drug Targets
Small RNAs: Association with Anthelmintic Resistance and as Potential New Drug Targets
Dominique Soldati-Favre,
University of Geneva, Switzerland
Short Talk: Plasmepsin IX and X: New Candidate Targets for Old Antimalarial Drugs
Short Talk: Plasmepsin IX and X: New Candidate Targets for Old Antimalarial Drugs
Conor Caffrey,
University of California, San Diego, USA
Short Talk: Automated Screening Technologies for Large Parasites
Short Talk: Automated Screening Technologies for Large Parasites
17:00—18:45
Pharmacokinetics and Informatics
*
Michael Riscoe,
Oregon Health & Science University, USA
*
Dennis E. Kyle,
University of Georgia, USA
Kevin Read,
University of Dundee, UK
Integrating Drug Metabolism and Pharmacokinetics into Antiparasitic Drug Discovery
Integrating Drug Metabolism and Pharmacokinetics into Antiparasitic Drug Discovery
Susan A. Charman,
Monash University, Australia
Human Pharmacokinetic and Dose Predictions for Neglected Diseases
Human Pharmacokinetic and Dose Predictions for Neglected Diseases
John Overington,
Medicines Discovery Catapult, UK
Informatics Approaches to Target Identification and Selection for Neglected Disease Drug Discovery
Informatics Approaches to Target Identification and Selection for Neglected Disease Drug Discovery
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions
*
Philip J. Rosenthal,
University of California, San Francisco, USA
19:00—20:00
Social Hour
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
